Literature DB >> 6883627

An investigation of the mouse as a model for vincristine toxicity.

S D Harrison.   

Abstract

The purpose of this study was to investigate the toxicologic responses of mice to vincristine (VCR), an established antitumor drug, and to compare them with those reported for dogs, monkeys, and humans. This comparison was expected to facilitate the continuing appraisal of the mouse as a model for toxicologic responses to antitumor drugs in human patients. In duplicate experiments, male B6D2F1 mice were treated with 1.0, 1.5, 2.0, and 3.0 mg/kg of VCR in single IP doses. These sublethal doses corresponded to 0.25, 0.40, 0.50, and 0.80 LD50. On posttreatment days 1, 3, 6, 10, 14, and 21, groups of mice were killed and blood and other tissues were collected for hematologic (8 tests), clinical chemical (15 tests), and histopathologic (11 tissues) evaluations. VCR produced dose-dependent body weight loss, reticulocytopenia, granulocytopenia, elevated plasma alkaline phosphatase, GPT, and GOT activities, and damage to the gastrointestinal epithelium. These reversible changes were most severe during the first 3 days posttreatment. The mouse was comparable to the dog and the monkey in reflecting the target organ toxicity of VCR in humans. Studies with additional antitumor drugs will be required before the overall predictive reliability of this model can be expressed quantitatively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883627     DOI: 10.1007/bf00257421

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Initial clinical studies with vincristine.

Authors:  G COSTA; M M HRESHCHYSHYN; J F HOLLAND
Journal:  Cancer Chemother Rep       Date:  1962-11

Review 2.  Clinical significance of an increased or decreased serum alkaline phosphatase level.

Authors:  P L Wolf
Journal:  Arch Pathol Lab Med       Date:  1978-10       Impact factor: 5.534

3.  Vincristine neurotoxicity in rodents.

Authors:  Q L Uy; T H Moen; R J Johns; A H Owens
Journal:  Johns Hopkins Med J       Date:  1967-11

4.  Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology.

Authors:  D J Prieur; D M Young; R D Davis; D A Cooney; E R Homan; R L Dixon; A M Guarino
Journal:  Cancer Chemother Rep 3       Date:  1973-01

5.  Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases.

Authors:  C R Smart; R E Ottoman; D B Rochlin; J Hornes; A R Silva; H Goepfert
Journal:  Cancer Chemother Rep       Date:  1968-12

6.  Vincristine (NSC-67574): a retrospective toxicologic evaluation in monkeys and dogs using weekly intravenous injections for 6 weeks.

Authors:  R M Folk; A C Peters; K L Pavkov; J A Swenberg
Journal:  Cancer Chemother Rep 3       Date:  1974-09

7.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Pharmacokinetics of vincristine sulfate in adult cancer patients.

Authors:  V S Sethi; D V Jackson; D R White; F Richards; J J Stuart; H B Muss; M R Cooper; C L Spurr
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

9.  Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice.

Authors:  S D Harrison; J A Burdeshaw; R G Crosby; A M Cusic; E P Denine
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

10.  Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice.

Authors:  S D Harrison
Journal:  Fundam Appl Toxicol       Date:  1981 Sep-Oct
View more
  4 in total

1.  Scyphocephalione A isolated from the stem bark of Scyphocephalium ochocoa (Myristicaceae) attenuate acute and chronic pain through the antiinflammatory activity.

Authors:  Marius Mbiantcha; Raymond Guy Feuya Tchouya; William Nana Yousseu; Donatien Albert Atsamo; Hibrahim Foundikou; Jacques Lebibi; Franklin Gamo Zemo
Journal:  Inflammopharmacology       Date:  2022-03-28       Impact factor: 4.473

2.  The mouse as a model for predicting the myelosuppressive effects of anticancer drugs.

Authors:  J E Schurig; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo.

Authors:  Yan Mu; Yin Liu; Liwen Li; Cong Tian; Hongyu Zhou; Qiu Zhang; Bing Yan
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

4.  Antinociceptive Activities of the Methanolic Extract of the Stem Bark of Boswellia dalzielii Hutch. (Burseraceae) in Rats Are NO/cGMP/ATP-Sensitive-K+ Channel Activation Dependent.

Authors:  Marius Mbiantcha; Alain Ngouonpe Wembe; Amadou Dawe; William Yousseu Nana; Gilbert Ateufack
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-06       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.